Filing Details

Accession Number:
0001305773-21-000050
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-18 21:21:30
Reporting Period:
2021-05-14
Accepted Time:
2021-05-18 21:21:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305773 Conformis Inc CFMS Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1481783 A Mark Augusti C/O Conformis, Inc.
600 Technology Park Drive
Billerica MA 01821
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-05-14 54,552 $0.76 2,151,465 No 4 S Direct
Common Stock Disposition 2021-05-17 7,311 $0.80 2,144,154 No 4 S Direct
Common Stock Disposition 2021-05-18 4,781 $0.81 2,139,373 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents the automatic sale of stock to cover the tax liability associated with the vesting of a Restricted Stock Award.
  2. The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $0.7600-$0.7892, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $0.7950-$0.8000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. This sale was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.